СОВРЕМЕННЫЕ ПОДХОДЫ К ДИАГНОСТИКЕ И ЛЕЧЕНИЮ БОЛЕЗНИ АЛЬЦГЕЙМЕРА

В статье приведены современные данные о причинах развития, методах диагностики и подходах  к лечению болезни Альцгеймера. Особое внимание уделено патогенетической и симптоматической терапии этого заболевания, а также нелекарственным методам лечения.

1. Захаров В.В., Яхно Н.Н. Нарушения памяти. М., 2001, 160 с.

2. Парфенов В.А., Захаров В.В., Преображенская И.С. Когнитивные расстройства. М., 2014, 224 с.

3. Яхно Н.Н., Захаров В.В., Локшина А.Б., Коберская Н.Н., Мхитарян Э.А. Деменции, руководство для врачей. 3-е изд. М.: «МЕДпресс-информ», 2011: 53-75.

4. Amenta F, Tayebati SK, Vitali D, Di Tullio MA. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. Mech Ageing Dev, 2006, 127: 173-179.

5. Amenta F. et al. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer’s disease with cerebrovascular injury: interim results. J. Neurol. Sci., 2012 Nov 15, 322(1-2): 96-101.

6. Amenta F et al. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. Mech Ageing Dev, 2006, 127(2):173-9.

7. Barnes DE, Yaffe K, Belfor N, Jagust WJ, DeCarli C, Reed BR, and Kramer JH. Computer-Based Cognitive Training for Mild Cognitive Impairment: Results from a Pilot Randomized, Controlled Trial Alzheimer Dis Assoc Disord. Author manuscript; available in PMC 2010 Jul1.Published in final edited form as: Alzheimer Dis Assoc Disord, 2009 Jul-Sep, 23(3): 205-210.

8. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol, (Berl), 1991, 82: 239-259.

9. Colcombe S & Kramer AF. Fitness effects on the cognitive function of older adults a metaanalytic study. Psychological science, 2003, 14(2): 125-130.

10. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. ClinTher, 2003, 25(1): 178-193.

11. Dickerson BC, Goncharova I, SullivanMP, Forchetti C,Wilson RS, Bennett DA, Beckett LA, deToledo-Morrell L. 2001.MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease. Neurobiol Agin 22: 747–754.

12. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology, 2007, 68: 501-508.

13. Gates N, Fiatarone Singh MA, Sachdev PS & Valenzuela M. The effect of exercise training on cognitive function in older adults with mild cognitive impairment: a meta-analysis of randomized controlled trials. The American Journal of Geriatric Psychiatry, 2013, 21(11): 1086-1097.

14. Iqbal K, del C Alonso A, Chen S et al. Tau pathology in Alzheimer disease and other tauopathies. Biochimica et Biophysica Acta (BBA), 2005 January 3, 1739(Issues 2-3): 198-210.

15. Jack CRJr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol, 2010, 9: 119-128.

16. Jay L, Whitwell JL. Dementia and Alzheimer’s disease: A new direction. The 2010. Foster Memorial Lecture. Longitudinal imaging: change and causality. Curr Opin Neurol, 2008, 21: 410-416.

17. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspective Medicine, 2012 April, 2(4): a006213.

18. Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM. Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study. Neurology, 2015 Jul 15. PMID: 26180144.

19. Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, et al. Rapid microglial response around amyloid pathology after systemic antiAbeta antibody administration in PDAPP mice. J Neurosci, 2008, 28(52): 14156-14164.

20. Magnoni S, Brody DL. New perspectives on amyloid-β dynamics after acute brain injury. Arch Neurol, 2010, 67: 1068-1073.

21. Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi Ch, Errico F, Mercuri NB, Nicoletti F, Nisticò R. Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease. Drug Design, Development and Therapy, 2013, 7: 1359-1364.

22. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol, 2012, 69(2): 198-207.

23. Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev, 2001, 122: 2041-55.

24. Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med, 2008, 148: 370-378.

25. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack Jr CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on AgingAlzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Нelp. Alzheimers Dement, 2011 May, 7(3): 280-292.

26. Rosen AC, Sugiura L, Kramer JH, WhitfieldGabrieli S, Gabrieli JD. Cognitive Training Changes Hippocampal Function in Mild Cognitive Impairment. A Pilot J Study Alzheimers Disease, 2011, 26(Suppl 3): 349-357.

27. Samadi H, Sultzer D. Solanezumab for Alzheimer’s disease. Expert Opin Biol Ther, 2011, 11(6): 787-798.

28. Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer’s disease: Unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci, 2002, 99: 4703-4707.

29. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, et al. Genomewide analysis of genetic loci associated with Alzheimer disease. JAMA, 2010, 303: 1832-1840.

30. Toyn JH, Rowley A, Matsuoka Y, Tomita T, Imbimbo BP. Γ-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer’s Disease? Int J Alzheimers Dis, 2013, 2013: 849128.

31. Veld BA, Launer LJ, Breteler MM, Hofman A, Stricker BH. Pharmacologic agents associated with preventive effect on Alzheimer’s disease: a review of the epidemiologic evidence. Epidemiol Rev, 2002, 24: 248–268. [PubMed: 12762096].

32. Weiner MW. Commentary on Diagnosis of Alzheimer’s disease: two decades of progress. Central role of technology in the treatment and prevention of Alzheimer’s disease. Alzheimers Dement, 2005, 1: 112-113.

33. Lulu Xie at al. Sleep drives metabolite clearance from the adult brain. Science, 2013, 342: 373.

34. Noh HJ, Joo EY, Kim ST et al. The Relationship between Hippocampal Volume and Cognition in Patients with Chronic Primary Insomnia. J Clin Neurol, 2012, 8(2): 130-138.